Empagliflozin vs Sitagliptin for Type 2 Diabetes Management

Introduction to Empagliflozin and Sitagliptin

• The American Diabetes Association recommends empagliflozin for patients with type 2 diabetes and established cardiovascular disease, due to its proven mortality reduction and cardiorenal protection benefits 1, 2
• Empagliflozin is specifically recommended for glycemic management and prevention of heart failure hospitalizations in patients with heart failure (reduced or preserved ejection fraction) 1

Cardiovascular and Mortality Outcomes

• Empagliflozin reduces hospitalization for heart failure by 35-36% in patients with type 2 diabetes 2
• The American College of Cardiology recommends empagliflozin for patients with type 2 diabetes and established cardiovascular disease, due to its proven mortality reduction benefits 1, 2
• Sitagliptin shows neutral cardiovascular effects, with no increase or decrease in cardiovascular events compared to placebo 2

Heart Failure Indications

• Empagliflozin reduces the composite of cardiovascular death or hospitalization for heart failure by 21% in heart failure with preserved ejection fraction 2
• The American Heart Association recommends empagliflozin for patients with heart failure (reduced or preserved ejection fraction) and type 2 diabetes, due to its proven benefits in reducing heart failure hospitalizations 1

Chronic Kidney Disease Benefits

• Empagliflozin is recommended for patients with CKD (eGFR 20-60 mL/min/1.73 m²) to minimize CKD progression, reduce cardiovascular events, and reduce heart failure hospitalizations 1, 4
• The National Kidney Foundation recommends empagliflozin for patients with CKD and type 2 diabetes, due to its proven benefits in reducing CKD progression and cardiovascular events 4

Safety Considerations

• Empagliflozin increases the risk of genital mycotic infections, which can be managed with hygiene counseling 7, 4
• The American College of Cardiology recommends holding empagliflozin during periods of acute illness or poor oral intake, due to the risk of euglycemic diabetic ketoacidosis 7, 4
• Sitagliptin is generally well tolerated with low adverse event rates, and can be safely continued during hospitalization for mild-to-moderate hyperglycemia 6

Clinical Decision Algorithm

• The American Diabetes Association recommends choosing empagliflozin for patients with established cardiovascular disease, heart failure, or CKD with eGFR 20-60 mL/min/1.73 m², due to its proven mortality reduction and cardiorenal protection benefits 1, 2
• Sitagliptin should only be considered when patients have contraindications to SGLT2 inhibitors, such as severe renal impairment with eGFR <20 mL/min/1.73 m², ESRD, or dialysis 7